Facing Patent Losses, Astellas Funds Genome Laboratory And Reorganizes Drug Discovery Functions
This article was originally published in PharmAsia News
Executive Summary
Astellas announced Sept. 1 it established the Genome Medical Science Laboratory at the University of Tokyo. The laboratory is looking to elucidate the mechanism of tumorigenesis through a large analysis of clinical samples using genomics technologies to develop new cancer treatments
You may also be interested in...
Pfizer And Astellas Ink Co-promotion Agreement For Hypertension And Cholesterol Combo Drug Caduet In Japan
TOKYO - Pfizer and Astellas Pharma have signed a co-promotion agreement for combination drug, Caduet (amlodipine and atorvastatin) for local Japanese distribution to treat both hypertension and hypercholesterolemia, the first combination drug for the two treatments, the two companies announced Aug. 26
Astellas Hits Walls In Fending Off Prograf Generics; Options Limited
WASHINGTON - Astellas' last ditch efforts to prevent the launch of Sandoz' generic Prograf (tacrolimus) failed last week, and as the company "evaluates its next course of action" for its top-selling product, its options do not look promising
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).